A Phase 1 interventional study of ABI-6250 in Mild Hepatic Imparement, sponsored by Assembly Biosciences. Not yet recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Assembly Biosciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to assess the safety, tolerability and pharmacokinetics of ABI-6250 in participants with mild hepatic impairment compared with participants with normal hepatic function.
Assembly Biosciences is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for Participants with Mild Hepatic Impairment (Cohort 1):
Inclusion Criteria for Participants with Normal Hepatic Function (Cohort 2):
Exclusion Criteria (All Participants):
Exclusion Criteria for Participants With Mild Hepatic Impairment (Cohort 1):
Exclusion Criteria for Participants With Normal Hepatic Function (Cohort 2):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ABI-6250
Participants will receive ABI-6250 0.5 mg QD over 10 days.
Maximum Observed Plasma Concentration (Cmax) of ABI-6250.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Apparent Terminal Elimination Half Life (t 1/2) of ABI-6250.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Time to Cmax (Tmax) of ABI-6250.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Area Under the Plasma Concentration-Time Curve (AUC) from time zero to 24 hours postdose (AUC0-24) of ABI-6250 on Days 1 and 10.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Apparent Systemic Clearance (CL/F) of ABI-6250.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Apparent Volume of Distribution (Vz/F) of ABI-6250.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Adverse events (AEs).
Time frame: From enrollment to Day 35.
Incidence of Clinically Significant Clinical Laboratory Parameters Abnormality.
Number of participants with at least one clinically significant laboratory parameters abnormality. The following parameters will be measured: Serum Chemistry: ALT, ALB, Alk phos, AST, BUN, Ca, Co2, Cl, Creatinine kinase, eGFR, GGT, Total Cholesterol, Trig, Glucose, LDH, Potassium, Sodium, T. Bili, D. Bili and I. Bili, Total protein. Hematology: HCT, HGB, MPV, Platelet count, RBC count, RBC indices (MCH, MCHC, MCV, RDW), WBC count, WBC differential (BASO, EOS, LYMPH, MONO, NEUT). Urinalysis: UCLA, UBILQL, UCOL, UGLUQ, UKET, UWEST, UNIT, UOCULT, pH, protein, Specific gravity. Coagulation: aPTT, PT, FIB, INR.
Time frame: From enrollment to Day 35, at pre-specified timepoints.
Incidence of Clinically Significant Vital Signs Abnormality.
Number of participants with at least one clinically significant vitals abnormality. The following clinical signs will be measured: systolic blood pressure (mmHg), diastolic blood pressure (mmHg), heart rate (beats/min), respiratory rate (breaths/min), and body temperature (C°).
Time frame: From enrollment to Day 35, at pre-specified timepoints.
Incidence of Clinically Significant 12-lead Electrocardiogram (ECG) Abnormality.
Number of participants with at least one clinically significant electrocardiogram abnormality. The following standard 12-lead ECG will be recorded: PR interval (msec), QRS duration (msec), QT interval (msec), QTCF interval (msec), heart rate (beats/min), RR (msec), and interpretation.
Time frame: From enrollment to Day 35, at pre-specified timepoints.
Incidence of Clinically Significant Physical Examination Abnormality.
Number of participants with at least one clinically significant physical abnormality. A complete physical examination, including at a minimum, assessments of the general appearance, respiratory, cardiovascular, gastrointestinal, musculoskeletal, and dermatological systems, in addition to examinations of the head, eyes, ears, nose, throat, neck, and lymph nodes, as well as height and weight measurement to calculate BMI.
Time frame: From enrollment to Day 35, at pre-specified timepoints.
Bile acid levels in plasma.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Coproporphyrin 1 (CP-1) levels in plasma.
Time frame: From Day 1 to Day 35, at pre-specified timepoints.
Unbound Cmax (Cmax,u) of ABI-6250.
Time frame: Day 1 and Day 10, at pre-specified timepoints.
Unbound AUC0-24 (AUC0-24,u) of ABI-6250.
Time frame: Day 1 and Day 10, at pre-specified timepoints.
Amount of bile acids excreted in urine.
Time frame: From Day 1 to Day 14, at pre-specified timepoints.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABI-6250